Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABBV 
AbbVie Inc (ABBV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: ABBV (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
28 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $243.55
1 Year Target Price $243.55
| 12 | Strong Buy |
| 4 | Buy |
| 12 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 22.83% | Avg. Invested days 46 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 406.92B USD | Price to earnings Ratio 175.76 | 1Y Target Price 243.55 |
Price to earnings Ratio 175.76 | 1Y Target Price 243.55 | ||
Volume (30-day avg) 28 | Beta 0.35 | 52 Weeks Range 160.33 - 243.06 | Updated Date 12/4/2025 |
52 Weeks Range 160.33 - 243.06 | Updated Date 12/4/2025 | ||
Dividends yield (FY) 2.92% | Basic EPS (TTM) 1.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When Before Market | Estimate 3.27 | Actual 1.86 |
Profitability
Profit Margin 4% | Operating Margin (TTM) 35.5% |
Management Effectiveness
Return on Assets (TTM) 9.59% | Return on Equity (TTM) 137.96% |
Valuation
Trailing PE 175.76 | Forward PE 16.39 | Enterprise Value 469994637671 | Price to Sales(TTM) 6.82 |
Enterprise Value 469994637671 | Price to Sales(TTM) 6.82 | ||
Enterprise Value to Revenue 7.88 | Enterprise Value to EBITDA 36.73 | Shares Outstanding 1767384632 | Shares Floating 1763938232 |
Shares Outstanding 1767384632 | Shares Floating 1763938232 | ||
Percent Insiders 0.1 | Percent Institutions 75.17 |
Upturn AI SWOT
AbbVie Inc
Company Overview
History and Background
AbbVie Inc. was founded in 2013 as a spin-off from Abbott Laboratories. It focuses on researching, developing, and marketing pharmaceutical products. A key milestone was the success of Humira and the acquisition of Allergan in 2020.
Core Business Areas
- Immunology: Develops and markets therapies for chronic immune-mediated inflammatory diseases, including Humira, Skyrizi, and Rinvoq.
- Oncology: Focuses on discovering and developing therapies for various cancers, including Imbruvica and Venclexta.
- Neuroscience: Develops treatments for neurological disorders, including migraine, Parkinson's disease, and Alzheimer's disease.
- Aesthetics: Includes products from the Allergan acquisition, such as Botox and Juvederm.
Leadership and Structure
AbbVie is led by CEO Richard A. Gonzalez. The company is structured around its core business segments, with distinct research and development, commercial, and operational functions.
Top Products and Market Share
Key Offerings
- Humira: A TNF blocker used to treat autoimmune diseases. Humira was a major revenue driver until biosimilar competition began in 2023. Competitors include Amgen's Amjevita, Novartis's Hyrimoz, and other biosimilars.
- Skyrizi: An interleukin-23 (IL-23) inhibitor used to treat psoriasis and Crohn's disease. Skyrizi is positioned as a key growth driver. Competitors are Janssen's Stelara and Eli Lilly's Taltz.
- Rinvoq: A JAK inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis. Competitors include Pfizer's Xeljanz and Eli Lilly's Olumiant.
- Botox: An injectable treatment for cosmetic and therapeutic purposes. Botox has a strong market presence in aesthetics. Competitors include Dysport and Xeomin.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, regulatory hurdles, patent protection, and strong competition. Demand is driven by aging populations, increasing prevalence of chronic diseases, and advancements in medical technology.
Positioning
AbbVie is a major player in the pharmaceutical industry, with a focus on innovative therapies and a strong presence in immunology, oncology, neuroscience, and aesthetics. Its competitive advantages include a strong product portfolio, robust pipeline, and experienced management team.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated at over $1 trillion. AbbVie is well-positioned to capture a significant share of this market through its diverse product portfolio and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Strong product portfolio
- Robust pipeline of new therapies
- Experienced management team
- Global presence
- Significant R&D investment
Weaknesses
- Reliance on key products such as Humira
- Exposure to biosimilar competition
- High debt levels from Allergan acquisition
- Potential for regulatory setbacks
- Dependence on successful R&D outcomes
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions and partnerships
- Growth in emerging markets
- Development of innovative therapies
- Increased demand for specialty pharmaceuticals
Threats
- Generic and biosimilar competition
- Pricing pressures from governments and payers
- Regulatory changes
- Product liability lawsuits
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
- NVS
- LLY
Competitive Landscape
AbbVie competes with other major pharmaceutical companies. AbbVie's strengths include its strong product portfolio and robust pipeline. Its weaknesses include its reliance on key products and exposure to generic competition.
Major Acquisitions
Allergan
- Year: 2020
- Acquisition Price (USD millions): 63000
- Strategic Rationale: Expanded AbbVie's product portfolio into aesthetics and other therapeutic areas.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was strong due to Humira sales. More recently growth has slowed down due to impending biosimilars but is expected to grow in the coming years.
Future Projections: Analysts expect revenue growth driven by new products such as Skyrizi and Rinvoq. Earnings growth is expected to be moderate.
Recent Initiatives: Recent initiatives include strategic acquisitions, partnerships, and investment in research and development.
Summary
AbbVie is a major pharmaceutical company with a strong product portfolio and robust pipeline. Its key strengths include its expertise in immunology and oncology. It faces challenges from biosimilar competition. AbbVie is positioned for growth through new product launches and strategic acquisitions.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AbbVie Inc
Exchange NYSE | Headquaters North Chicago, IL, United States | ||
IPO Launch date 2013-01-02 | CEO & Chairman of the Board Mr. Robert A. Michael CPA | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 55000 | Website https://www.abbvie.com |
Full time employees 55000 | Website https://www.abbvie.com | ||
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.